By Daniella Parra Sequana Medical said the first implantation of the alfapump in the U.S. at Mount Sinai Hospital received FDA approval for the treatment of recurrent or refractory ascites due to liver cirrhosis. Sequana is working to relieve patients...

By Karen Roman Imviva Biotech said it will present its progress in allogenic cell therapy candidates in two oral presentations and five poster presentations at the 67th American Society of Hematology (ASH) Annual Meeting, to be held on December 6-9,...

By Daniella Parra March Biosciences said that the FDA granted regenerative medicine advanced therapy its first-in-class CD5-targeted CAR-T cell therapy for relapsed or refractory CD5-positive T-cell lymphoma. The designation is based on encouraging early Phase 2 data showing clinical activity and...

By Daniella Parra Radiant Biotherapeutics presented data from their advancing a breakthrough antibody approach, the Multabody which uniquely harnesses natural mechanisms to effectively engage multiple disease targets with unmatched strength, precise tunability, and exceptional breadth, they said. They said RBT-101 achieved...

By Karen Roman Agilent Technologies, Inc. (NYSE: A) said it appointed Adam S. Elinoff as Chief Financial Officer starting on Nov. 17, who joins from having previously served Amgen as its vice president of finance and treasurer. Mr. Elinoff has...

By Karen Roman Biopharmaceutical company Medera Inc. said the first patient has been dosed in Phase 2 of its MUSIC-HFrEF clinical trial using gene therapy for heart failure with reduced ejection fraction. The advancement comes after a positive recommendation and...

By Karen Roman Oncology-focused biotech company SkylineDx said results from its MERLIN_001 trial, the largest evaluation of a genomic test in cutaneous melanoma, were published in the October 2025 issue of JAMA Surgery. The study shows the test classified T1-T3...

By Daniella Parra Ashvattha Therapeutics has appointed Robert J. Dempsey as Interim CEO, tapping an ophthalmology veteran with a track record of transformative deals and launches, they said. Recently, Ashvattha announced positive Phase 2 results for migaldendranib, a novel subcutaneous nanomedicine showing...

By Karen Roman Lisata Therapeutics, Inc. (Nasdaq: LSTA) said it started a global product license agreement with Catalent, Inc., enabling the latter to include Lisata’s certepetide into antibody-drug conjugates (ADCs) developed using Catalent’s SMARTag technology platform. The partnership is a...

By Daniella Parra NanoCell Therapeutics, Inc. has appointed three new members to its Scientific Advisory Board: Prof. Zoltán Ivics, PhD; Jens Hasskarl, MD, PhD; and Jake Brenner, MD, PhD, they said. NanoCell said the new appointments add critical expertise spanning...